A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Drug-induced kidney injury, or nephrotoxicity, is a common complication in clinical medicine that happens when drugs damage ...

Researchers have identified six new biomarkers that could detect kidney injury faster and with more sensitivity, advancing safer drug development and improving health outcomes for patients. The new ...

Sage Therapeutics, Inc. today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San ...

These are designed to have the affinity and selective pharmacology of antibodies ... Established investor Vertex Ventures HC led the financing round, but the biotech also attracted new investors ...

He is an Associate Professor in the Department of Pharmacology and Therapeutics ... a beta cell therapy company acquired by Vertex in 2022. Through her expertise in stem cell therapy disease ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...